Indaptus Therapeutics Inc (INDP)

$0.47 -0.03 (-5.04%)
Market Cap 7.55M
Revenue (ttm) 0.00
Net Income (ttm) -15.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 27,100
Avg Vol 512,814
Day's Range N/A - N/A
Shares Out 16.03M
Stochastic %K 27%
Beta 1.62
Analysts Strong Sell
Price Target $7.00

Latest News on INDP

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Mar 25, 2025, 8:00 AM EDT - 4 weeks ago

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Mar 20, 2025, 8:00 AM EDT - 5 weeks ago

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Mar 18, 2025, 8:00 AM EDT - 5 weeks ago

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Mar 13, 2025, 7:30 AM EDT - 6 weeks ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Mar 12, 2025, 4:15 PM EDT - 6 weeks ago

Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Mar 4, 2025, 8:00 AM EST - 7 weeks ago

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Feb 25, 2025, 8:00 AM EST - 2 months ago

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Feb 5, 2025, 8:00 AM EST - 2 months ago

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Jan 8, 2025, 8:00 AM EST - 3 months ago

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Nov 22, 2024, 8:36 AM EST - 5 months ago

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Nov 11, 2024, 8:00 AM EST - 5 months ago

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Nov 7, 2024, 8:00 AM EST - 6 months ago

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

Oct 23, 2024, 8:00 AM EDT - 6 months ago

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Apr 11, 2024, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:30 AM EDT - 1 year ago

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 13, 2024, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Mar 4, 2024, 7:30 AM EST - 1 year ago

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Feb 8, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Jan 4, 2024, 8:00 AM EST - 1 year ago

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 4:01 PM EST - 1 year ago

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Oct 31, 2023, 9:01 AM EDT - 1 year ago

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:05 AM EDT - 1 year ago

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 14, 2023, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Aug 10, 2023, 8:45 AM EDT - 1 year ago

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

Aug 7, 2023, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023, 7:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

May 9, 2023, 8:00 AM EDT - 2 years ago

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

May 1, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

Apr 20, 2023, 4:05 PM EDT - 2 years ago

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Apr 19, 2023, 9:28 AM EDT - 2 years ago

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Apr 19, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Indaptus Therapeutics to Present at the Investor Summit Conference

Mar 22, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the Investor Summit Conference

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Mar 17, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

Mar 15, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Mar 13, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Mar 7, 2023, 8:05 AM EST - 2 years ago

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

Feb 14, 2023, 8:00 AM EST - 2 years ago

Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Feb 7, 2023, 8:05 AM EST - 2 years ago

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Dec 13, 2022, 7:30 AM EST - 2 years ago

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 10, 2022, 4:05 PM EST - 2 years ago

Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Indaptus Therapeutics to Present at the LD Micro Main Event XV

Oct 18, 2022, 7:00 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the LD Micro Main Event XV

Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

Sep 6, 2022, 9:02 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 8, 2022, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference

Jun 9, 2022, 7:00 AM EDT - 3 years ago

Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference

Indaptus Therapeutics to Present at Jefferies Healthcare Conference

Jun 3, 2022, 7:00 AM EDT - 3 years ago

Indaptus Therapeutics to Present at Jefferies Healthcare Conference

Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

May 19, 2022, 7:00 AM EDT - 3 years ago

Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference

May 18, 2022, 4:15 PM EDT - 3 years ago

Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference

Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 12, 2022, 8:00 AM EDT - 3 years ago

Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update